Masahiro Tsuboi

16PUBLICATIONS
120CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersTumour immunologyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Jun 02, 2025
Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small Cell Lung Cancer.

Jianxing He, Masahiro Tsuboi, Walter Weder

|Oct 25, 2024
Efficacy, Safety, and Influence on the Tumor Microenvironment of Neoadjuvant Pembrolizumab plus Ramucirumab for PD-L1-Positive NSCLC: A Phase II Trial (EAST ENERGY).

Keiju Aokage, Shohei Koyama, Shogo Kumagai

|Sep 29, 2023
Metabolic Hallmarks for Purine Nucleotide Biosynthesis in Small Cell Lung Carcinoma.

Sho Tabata, Shigeki Umemura, Miyu Narita

|Sep 01, 2023
Five-Year Overall Survival Analysis of the JIPANG Study: Pemetrexed or Vinorelbine Plus Cisplatin for Resected Stage II-IIIA Nonsquamous Non-Small-Cell Lung Cancer.

Hirotsugu Kenmotsu, Nobuyuki Yamamoto, Toshihiro Misumi

|Jan 31, 2023
Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial.

Roy S Herbst, Yi-Long Wu, Thomas John

|Oct 07, 2022
BATF epigenetically and transcriptionally controls the activation program of regulatory T cells in human tumors.

Kota Itahashi, Takuma Irie, Junichiro Yuda

Pageof 3

Frequent Collaborators

4 joint publications

Genichiro Ishii

3 joint publications

Hiroyoshi Nishikawa

3 joint publications

Shohei Koyama

3 joint publications

Yi-Long Wu